- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Arrowhead Research Corporation (Nasdaq:ARWR), announced today that R. Bruce Stewart, Chairman of Arrowhead, and Sean Olson, President of Arrowhead's majority-owned subsidiary, Unidym, have been selected to present at the ThinkEquity Partners Private Company and Venture Capital Summit in San Francisco on May 9. Mr. Stewart will participate in the panel discussion "Think Tiny" moderated by Stuart Pulvirent of ThinkEquity Partners.
A life-long entrepreneur, Mr. Stewart has started and funded more than eighteen companies and has taken several of them to the public markets. His capital market experience spans thirty years and he has raised substantial capital for both public and private companies. He is known for his success in building value for shareholders and innovating novel strategies in corporate finance. Prior to founding Arrowhead Research, Mr. Stewart founded Acacia Research Corporation which he took public in 1995. During Mr. Stewart's eight-year tenure, Acacia built a portfolio of subsidiary companies operating in the areas of biotechnology, media technology licensing, direct marketing and early internet applications, and reached a market cap of close to $1 billion. Mr. Stewart gained much of his knowledge and experience in corporate finance as President of Annandale Securities from 1977 to 1992, an investment banking firm and registered broker dealer.
Mr. Olson's presentation entitled "Carbon Nanotechnology for Electronics" will highlight Unidym's progress in commercializing carbon nanotubes (CNTs) for applications in the electronics industry. Mr. Olson will also describe Unidym's first two products: CNT-based transparent electrodes for flat panel displays and CNT-based thin film transistors.
Mr. Olson has both technical and business experience in the semiconductor industry and is a veteran of both early and late stage ventures. Previously, Mr. Olson led Aonex Technologies, an Arrowhead subsidiary developing novel materials for the blue LED industry. Mr. Olson also served in engineering and management positions at Silicon Valley Group Lithography (acquired by ASML), a semiconductor capital equipment provider, and was a strategy consultant for The Boston Consulting Group. He received engineering degrees from the Massachusetts Institute of Technology and an MBA from The Harvard Business School.
About Arrowhead Research Corporation
Arrowhead Research Corporation ( http://www.arrowheadresearch.com ) is a publicly-traded nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is building value for shareholders through the progress of majority owned subsidiaries founded on nanotechnologies originally developed at universities. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has four subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, carbon-based electronics and compound semiconductor materials.
About Unidym, Inc.
Unidym is a leader in the manufacture and application of carbon nanotubes (CNTs), a novel material with extraordinary electrical, thermal, and mechanical properties. Unidym provides bulk materials, CNT-enabled products, and intellectual property to a wide range of customers and business partners. As a result of its recent merger with CNI, Unidym possesses a foundational patent portfolio that covers nearly every aspect of CNT manufacturing and processing as well as multiple product applications.
Unidym is focused on the electronics industry where its initial products include transparent electrodes for touch screens, flat panel displays, solar cells, and solid state lighting; electrodes for fuel cells; and thin film transistors for printable electronics. Unidym is also pursuing an aggressive, cross-industry partnership strategy to capture value from the wide ranging uses of CNTs. Undiym’s licensing program, technical expertise and manufacturing facilities can enable partners to rapidly develop CNT solutions for their specific applications.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K and 10-K/A, recent and forthcoming Quarterly Reports on Form 10-Q and 10-Q/A, recent Current Reports on Forms 8-K and 8-K/A, our Registration Statements on Form S-3, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.
For more information, please click here
Arrowhead Research Corporation
Virginia E. Dadey, 212-541-3707
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Nanotech Grants Options September 22nd, 2016
Arrowhead Pharmaceuticals to Present at Upcoming September Conferences September 1st, 2016
Industrial Nanotech, Inc. Provides Shareholder Update August 22nd, 2016
Metamaterial device allows chameleon-like behavior in the infrared October 28th, 2016
The molecular mechanism that blocks membrane receptors has been identified: The work in which the Ikerbasque researcher of the Biofisika Institute Xabier Contreras has participated has been published in the journal Cell October 27th, 2016
Imaging where cancer drugs go in the body could improve treatment October 26th, 2016
Leti Scientists Participating in Sessions on Med Tech, Automotive Technologies, MEMS, Si-photonics and Lithography at SEMICON Europa: Teams also Will Demonstrate Technology Advances in Telecom, Data Fusion, Energy, Silicon Photonics and 3D Integration October 18th, 2016